Castelo, B. (Beatriz)

Filtering

20212

Settings

Author search.filters.isAuthorOfPublication.7ac3977c-6dd5-463e-bb5f-a7f0cf681c43

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases
    (2021) Gallego-Martínez, A. (Alejandro); Yébenes, L. (Laura); Mendiola, M. (Marta); Garrido, D. (Diego); Castelo, B. (Beatriz); Redondo, A. (Andrés)
    A 51-year-old woman with an unremarkable personal and family medical history sought medical attention after noticing an abdominal mass, which was located mainly in the right iliac fossa. A gynecological ultrasound and a CT body scan showed a 22.3×11.5 cm pelvic mass dependent on both ovaries, with peritoneal implants, retroperitoneal lymph nodes, and ascites, without supra-diaphragmatic disease, associated with a serum CA125 level of 2634 kIU/L. The patient first underwent an exploratory laparoscopy, and later a complete cytoreduction was performed with hysterectomy, bilateral salpingo-oophorectomy, omentectomy, appendectomy, pelvic and para-aortic lymphadenectomy, and resection of tumor implants and the transverse, descending, and sigmoid colon. The histopathological examination confirmed the diagnosis of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC high-grade serous ovarian carcinoma (Figure 1). After primary cytoreduction, the patient received six cycles of carboplatin, area under the curve 6 mg/mL/min, and paclitaxel 175 mg/m2 every 3 weeks. At the end of the treatment no disease remained on the CT scan and the CA125 level was normal.
  • Thumbnail Image
    Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study
    (2021) Gallego-Martínez, A. (Alejandro); Ruiz-Giménez, L. (Leticia); Martínez, B. (Beatriz); Ghanem, I. (Ismael); Feliu-Batlle, J. (Jaime); Cantero, J. M. (José Miguel); Zamora-Auñon, P. (Pilar); Espinosa, E. (Enrique); Castelo, B. (Beatriz); Redondo, A. (Andrés)
    Purpose Long-term cancer survivors (LTCS) are a vulnerable and continued growing population. To date, only few studies have been conducted in the Spanish population; none of them with a comprehensive analysis of the most common problems identified for cancer survivors in order to improve their care and quality of life. Methods We conducted an observational descriptive study in 347 patients recruited between January 2015 and December 2016 from our newly created medical office for the specific care and follow-up of LTCS. Variables that describe the medical history were completed by the oncologist and measures on common problems previously reported for LTCS, related to cancer diagnosis and treatment, function, lifestyle, and emotional concerns, were collected from the patient. Results The mean age of our patients was 65.1 years at the time of the study and a median time without any antitumor treatment of 5.7 years. At the time of cancer diagnosis, 298 patients (85.9%) had at least one related chronic disease and 184 patients (53%) were retired. In addition, in 17.9% of those who continued working, income had been reduced. The incidence of health problems showed an increase during follow-up, even after 5 years, and required evaluation in an emergency department in 157 cases (45.3%). Regardless of age or sex, 239 patients (68.9%) had a significant decrease in sexual activity and 120 (34.6%) were diagnosed with clinical depression. Conclusions LTCS are patients with significantly high socioeconomic, labor, sexual, health, and psychological problems, 5 years after completion of cancer treatment, especially in older survivors. Implications for Cancer Survivor Common concerns of LTCS were identified and are consistent across many countries. It is important to realize that even 5 or so years following treatment, both medical and non-medical problems can exist and may need attention by an expert.